WCM Investment Management LLC Buys 108,775 Shares of Haleon PLC Sponsored ADR (NYSE:HLN)

WCM Investment Management LLC raised its stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 34.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 422,487 shares of the company's stock after purchasing an additional 108,775 shares during the quarter. WCM Investment Management LLC's holdings in Haleon were worth $4,326,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Farther Finance Advisors LLC raised its holdings in shares of Haleon by 8.8% during the first quarter. Farther Finance Advisors LLC now owns 12,861 shares of the company's stock worth $131,000 after acquiring an additional 1,041 shares during the period. Simplicity Wealth LLC increased its holdings in shares of Haleon by 7.9% during the 1st quarter. Simplicity Wealth LLC now owns 15,482 shares of the company's stock worth $159,000 after acquiring an additional 1,135 shares during the last quarter. Haverford Trust Co grew its stake in Haleon by 5.0% in the 4th quarter. Haverford Trust Co now owns 25,842 shares of the company's stock valued at $247,000 after buying an additional 1,233 shares during the last quarter. Bessemer Group Inc. lifted its holdings in Haleon by 5.9% during the 4th quarter. Bessemer Group Inc. now owns 22,301 shares of the company's stock worth $212,000 after purchasing an additional 1,236 shares during the last quarter. Finally, United Capital Financial Advisors LLC raised its stake in Haleon by 3.5% in the 4th quarter. United Capital Financial Advisors LLC now owns 37,475 shares of the company's stock worth $358,000 after purchasing an additional 1,266 shares in the last quarter. Institutional investors own 6.67% of the company's stock.

Haleon Stock Performance

Shares of HLN traded up $0.10 on Thursday, reaching $10.36. The company's stock had a trading volume of 8,422,996 shares, compared to its average volume of 9,466,150. The stock has a market capitalization of $46.54 billion, a P/E ratio of 26.55, a PEG ratio of 2.95 and a beta of 0.25. The company has a debt-to-equity ratio of 0.53, a current ratio of 0.98 and a quick ratio of 0.78. The stock's 50 day simple moving average is $10.72 and its two-hundred day simple moving average is $10.14. Haleon PLC Sponsored ADR has a 12-month low of $8.37 and a 12-month high of $11.42.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. HSBC reiterated a "hold" rating on shares of Haleon in a research note on Wednesday, March 5th. BNP Paribas raised shares of Haleon to a "strong-buy" rating in a research note on Tuesday, May 27th. Morgan Stanley upgraded shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price target for the company in a research note on Friday, May 9th. BNP Paribas Exane upgraded Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price objective on the stock in a research note on Tuesday, May 27th. Finally, Hsbc Global Res lowered Haleon from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Five research analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $12.33.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.